AcelRx Pharmaceuticals, Inc. (ACRX)
Total Valuation
ACRX has a market cap or net worth of $12.46 million. The enterprise value is -$929,059.
| Market Cap | 12.46M |
| Enterprise Value | -929,059 |
Important Dates
The last earnings date was Wednesday, November 8, 2023, after market close.
| Earnings Date | Nov 8, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
ACRX has 16.95 million shares outstanding. The number of shares has increased by 127.16% in one year.
| Shares Outstanding | 16.95M |
| Shares Change (YoY) | +127.16% |
| Shares Change (QoQ) | +53.40% |
| Owned by Insiders (%) | 2.64% |
| Owned by Institutions (%) | 38.89% |
| Float | 12.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 1.06 |
| PS Ratio | 20.03 |
| Forward PS | n/a |
| PB Ratio | 0.68 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.04, with zero debt.
| Current Ratio | 4.04 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.96 |
Financial Efficiency
Return on equity (ROE) is -163.50% and return on invested capital (ROIC) is -109.46%.
| Return on Equity (ROE) | -163.50% |
| Return on Assets (ROA) | -92.30% |
| Return on Capital (ROIC) | -109.46% |
| Revenue Per Employee | $32,737 |
| Profits Per Employee | -$1.39M |
| Employee Count | 19 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ACRX has paid $4,000 in taxes.
| Income Tax | 4,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -65.49% in the last 52 weeks. The beta is 0.64, so ACRX's price volatility has been lower than the market average.
| Beta (1Y) | 0.64 |
| 52-Week Price Change | -65.49% |
| 50-Day Moving Average | 0.64 |
| 200-Day Moving Average | 0.81 |
| Relative Strength Index (RSI) | 50.64 |
| Average Volume (30 Days) | 117,596 |
Short Selling Information
The latest short interest is 508,110, so 3.00% of the outstanding shares have been sold short.
| Short Interest | 508,110 |
| Short Previous Month | 520,611 |
| Short % of Shares Out | 3.00% |
| Short % of Float | 4.23% |
| Short Ratio (days to cover) | 4.56 |
Income Statement
In the last 12 months, ACRX had revenue of $622,000 and -$26.48 million in losses. Loss per share was -$2.97.
| Revenue | 622,000 |
| Gross Profit | 260,000 |
| Operating Income | -20.04M |
| Pretax Income | -21.36M |
| Net Income | -26.48M |
| EBITDA | -19.94M |
| EBIT | -20.60M |
| Loss Per Share | -$2.97 |
Balance Sheet
The company has $13.39 million in cash and no debt, giving a net cash position of $13.39 million or $0.79 per share.
| Cash & Cash Equivalents | 13.39M |
| Total Debt | n/a |
| Net Cash | 13.39M |
| Net Cash Per Share | $0.79 |
| Equity / Book Value | 18.31M |
| Book Value Per Share | 1.08 |
| Working Capital | 10.85M |
Cash Flow
In the last 12 months, operating cash flow was -$18.96 million and capital expenditures -$148,000, giving a free cash flow of -$19.10 million.
| Operating Cash Flow | -18.96M |
| Capital Expenditures | -148,000 |
| Free Cash Flow | -19.10M |
| FCF Per Share | -$1.14 |
Margins
Gross margin is 41.80%, with operating and profit margins of -3,221.70% and -4,256.43%.
| Gross Margin | 41.80% |
| Operating Margin | -3,221.70% |
| Pretax Margin | -3,434.08% |
| Profit Margin | -4,256.43% |
| EBITDA Margin | -3,206.27% |
| EBIT Margin | -3,311.25% |
| FCF Margin | -3,071.38% |
Dividends & Yields
ACRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -212.48% |
| FCF Yield | -153.32% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -127.16% |
| Shareholder Yield | -127.16% |
Analyst Forecast
The average price target for ACRX is $4.63, which is 529.93% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.63 |
| Price Target Difference | 529.93% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 80.32% |
| EPS Growth Forecast (5Y) | -26.15% |
Stock Splits
The last stock split was on October 26, 2022. It was a reverse split with a ratio of 1:20.
| Last Split Date | Oct 26, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
ACRX has an Altman Z-Score of -27.29 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -27.29 |
| Piotroski F-Score | 3 |